MOONLAKE IMMUNO (MLTX)
(Delayed Data from NSDQ)
$51.04 USD
+4.62 (9.95%)
Updated Sep 12, 2024 03:59 PM ET
After-Market: $51.02 -0.02 (-0.04%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$51.04 USD
+4.62 (9.95%)
Updated Sep 12, 2024 03:59 PM ET
After-Market: $51.02 -0.02 (-0.04%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Zacks News
Wall Street Analysts Believe MoonLake Immunotherapeutics (MLTX) Could Rally 26.97%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 27% upside potential for MoonLake Immunotherapeutics (MLTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is MoonLake Immunotherapeutics (MLTX) Stock a Solid Choice Right Now?
by Zacks Equity Research
MoonLake Immunotherapeutics (MLTX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
ACELYRIN (SLRN) Fails to Meet Goal in HS Study, Stock Down 54%
by Zacks Equity Research
ACELYRIN (SLRN) fails to achieve statistically significant primary endpoint result in the hidradenitis suppurativa study of its lead candidate, izokibep. The stock of the company falls 54%.
Biotech Stock Roundup: SRPT's DMD Therapy Approval, ICPT's Setback & More Updates
by Zacks Equity Research
Regulatory updates from Sarepta (SRPT) and Intercept (ICPT) are in focus in the biotech sector.
MoonLake Immunotherapeutics (MLTX) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
MoonLake Immunotherapeutics (MLTX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Why MoonLake (MLTX) Might Surprise This Earnings Season
by Zacks Equity Research
MoonLake (MLTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Here's Why Momentum in MoonLake Immunotherapeutics (MLTX) Should Keep going
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, MoonLake Immunotherapeutics (MLTX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
MoonLake Immunotherapeutics (MLTX) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, MoonLake Immunotherapeutics (MLTX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
What Makes MoonLake Immunotherapeutics (MLTX) a New Buy Stock
by Zacks Equity Research
MoonLake Immunotherapeutics (MLTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.